User:Mr. Ibrahem/Cemiplimab

Cemiplimab, sold under the brand name Libtayo, is a medication used to treat squamous cell skin cancer, basal cell cancer, and certain non-small cell lung cancer (NSCLC). It is used for advanced cases that cannot be cured by surgery. It is given by injection into a vein.

Common side effects include low thyroid with tiredness and weight gain; pneumonitis with shortness of breath and cough; skin reactions; high thyroid with sweating and weight; and inflammation of the liver. Other side effects may include infusion reactions and muscle pain. Use during pregnancy may harm the baby. It is a monoclonal antibody that binds to programmed death receptor-1 (PD-1), allowing T cells to kill cancer cells.

Cemiplimab was approved for medical use in the United States in 2018 and Europe in 2019. It was approved for medical use in Australia in July 2020. In the United Kingdom it costs the NHS £4,650 every 3 weeks. This amount in the United States costs about $9,800.